相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy
Mette Ilander et al.
LEUKEMIA & LYMPHOMA (2014)
Selective killing of candidate AML stem cells by antibody targeting of IL1RAP
Maria Askmyr et al.
BLOOD (2013)
Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling
Hugues de Lavallade et al.
BLOOD (2013)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille Abboud et al.
BLOOD (2013)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross et al.
BLOOD (2013)
Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib
Izuru Mizoguchi et al.
CANCER SCIENCE (2013)
CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
Patrick A. Ott et al.
CLINICAL CANCER RESEARCH (2013)
Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients
Giorgio La Nasa et al.
EXPERIMENTAL HEMATOLOGY (2013)
Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study
Takayoshi Uchiyama et al.
HEMATOLOGICAL ONCOLOGY (2013)
Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy
S. Mustjoki et al.
LEUKEMIA (2013)
Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients
S. Mustjoki et al.
LEUKEMIA (2013)
Graft-versus-leukemia Effect of HLA-haploidentical Central-memory T-cells Expanded With Leukemic APCs and Modified With a Suicide Gene
Monica Casucci et al.
MOLECULAR THERAPY (2013)
Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion
Yared Hailemichael et al.
NATURE MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
Lisa Christiansson et al.
PLOS ONE (2013)
Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia
Sara Ali et al.
BLOOD (2012)
Increased natural killer cells and decreased CD3+CD8+CD62L+T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib
Kazuma Ohyashiki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Mutated BCR-ABL Generates Immunogenic T-cell Epitopes in CML Patients
Ann Cai et al.
CLINICAL CANCER RESEARCH (2012)
Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients
Alexis Rossignol et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia
Anna Kreutzman et al.
EXPERIMENTAL HEMATOLOGY (2012)
Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib
Nicole Hassold et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa
Hidehiro Itonaga et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2012)
Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients
Hideo Tanaka et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2012)
Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib
D. Marin et al.
LEUKEMIA (2012)
NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice
Ci-U Chen et al.
LEUKEMIA (2012)
Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib
Yoshiki Hayashi et al.
LEUKEMIA & LYMPHOMA (2012)
Characterization of chronic myeloid leukemia stem cells
Jonathan M. Gerber et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
Bengt Simonsson et al.
BLOOD (2011)
Quantitative and functional analyses of CD4+CD25+FoxP3+ regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate
Emmanuel Bachy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Antigens in chronic myeloid leukemia: implications for vaccine development
Michal Smahel
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Dasatinib Combined with Interferon-alfa Induces a Complete Cytogenetic Response and Major Molecular Response in a Patient with Chronic Myelogenous Leukemia Harboring the T315I BCR-ABL1 Mutation
A. Megan Cornelison et al.
Clinical Lymphoma Myeloma & Leukemia (2011)
Expression and distribution of PPP2R5C gene in leukemia
Haitao Zheng et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation
A. Kreutzman et al.
LEUKEMIA (2011)
Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile
Anna Kreutzman et al.
PLOS ONE (2011)
Natural Killer Cell Mediated Missing-Self Recognition Can Protect Mice from Primary Chronic Myeloid Leukemia In Vivo
Mika Kijima et al.
PLOS ONE (2011)
Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia
Peter G. Maslak et al.
BLOOD (2010)
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy
Anna Kreutzman et al.
BLOOD (2010)
Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy
Peter Rohon et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
The BCR/ABL-inhibitors Imatinib, Nilotinib and Dasatinib differentially affect NK cell reactivity
Julia Salih et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia
Andreas Burchert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia.
Claude Preudhomme et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein
Marcus Jaras et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Aurora-A kinase: a novel target of cellular immunotherapy for leukemia
Toshiki Ochi et al.
BLOOD (2009)
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib
Roberto M. Lemoli et al.
BLOOD (2009)
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
Ulrich Keilholz et al.
BLOOD (2009)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
S. Mustjoki et al.
LEUKEMIA (2009)
Profound inhibition of antigen-specific T-cell effector functions by dasatinib
Ralf Weichsel et al.
CLINICAL CANCER RESEARCH (2008)
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
A. Hochhaus et al.
LEUKEMIA (2008)
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation
Andrew E. Schade et al.
BLOOD (2008)
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies
Katayoun Rezvani et al.
BLOOD (2008)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Hagop M. Kantarjian et al.
BLOOD (2007)
Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells
Heather G. Jorgensen et al.
BLOOD (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes
J. H. Kessler et al.
LEUKEMIA (2006)
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
Mhairi Copland et al.
BLOOD (2006)
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner
R Seggewiss et al.
BLOOD (2005)
Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase
H Fujiwara et al.
BLOOD (2004)
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia
K Cathcart et al.
BLOOD (2004)
Immunological effects of interferon-alpha on chronic myelogenous leukemia
FA de Castro et al.
LEUKEMIA & LYMPHOMA (2003)
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
R Bhatia et al.
BLOOD (2003)
Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia
J Grenier et al.
EXPERIMENTAL HEMATOLOGY (2002)
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
SM Graham et al.
BLOOD (2002)
分享论文
